Bristol Myers Squibb Reports Phase 2b Data for Durvalumab in Migraine

Bristol Myers Squibb today announced Phase 2b results for durvalumab in patients with migraine. The study demonstrated that durvalumab improves quality of life compared to standard of care or placebo. These results provide important insights into the treatment of migraine and support the continued development of durvalumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.